Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL292719 | 0.75 | ALDH1A1 (0.37) | — | |
| SCHEMBL10704444 | 0.67 | ALDH1A1 (0.33) | ENPP3ENPP1 | |
| SCHEMBL25305765 | 0.66 | ENPP1 (0.42) | ENPP3ENPP1 | |
| SCHEMBL29978062 | 0.66 | ALDH1A1 (0.32) | — | |
| SCHEMBL24009703 | 0.66 | ALDH1A1 (0.32) | — | |
| SCHEMBL6238742 | 0.66 | ALDH1A1 (0.32) | — | |
| SCHEMBL28687107 | 0.64 | ENPP1 (0.35) | ENPP3ENPP1 | |
| SCHEMBL29349643 | 0.64 | ENPP1 (0.35) | ENPP3ENPP1 | |
| SCHEMBL19024150 | 0.64 | ATF1 (0.33) | — | |
| SCHEMBL1323446 | 0.61 | ALDH1A1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718654-B2 | Substituted pteridines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-18 | — | — | US | disclosed |
| EP-1819707-A2 | SUBSTITUTED PTERIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006058867-A2 | SUBSTITUTED PTERIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-08 | — | — | WO | disclosed |
| US-20060116371-A1 | Substituted pteridines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116371-A1 | Substituted pteridines for the treatment of inflammatory diseases | LTC4S, TLR5, LTB4R2 | ENPP3 171/4885ENPP1 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.